Moderna, Inc. (NASDAQ:MRNA) Q2 2023 Earnings Call Transcript

Stephen Hoge: The only thing I’d add to that in terms of the development side is we are obviously looking at multiple different versions of RSV combination vaccines, and one of the advantages there will obviously be increased convenience and compliance. And that’s where if we can create healthcare system value, I think it will be – it will continue to evolve, the recommendation that people have around that. As it relates to CMV, so we haven’t set out a guidance on when we would expect the enrollment to complete. But we’re actually confident, given the trajectory that we’re already past 80%, that we will complete enrollment this year. I’m not saying this quarter, but this year. And as I said, what really matters is probably not whether we’re at 80% or 99% or 100% enrollment.

It’s the accrual of cases and events will drive the first interim analysis from here forward. Now, obviously, more patients – more participants enrolled will increase the number of – and pace of those events over time. And so, we are focused very much on that operationally, and we do hope to have that completed this year.

Operator: And I’d like to turn the call back to Stéphane for any closing remarks.

Stéphane Bancel: Well, thank you very much for your questions. We look forward to seeing many of you in the next days and weeks, but especially seeing you at the R&D Day on September 13 to see many of you in person. Have a great day. Thank you.

Operator: Ladies and gentlemen, this does conclude today’s presentation. You may now disconnect and have a wonderful day.